AcelRx Pharmaceuticals, Inc. (ACRX) At $2.40 Forms Bottom; Cerner (CERN) Has 1.05 Sentiment

AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) Logo

Cerner Corp (CERN) investors sentiment increased to 1.05 in 2017 Q4. It’s up 0.07, from 0.98 in 2017Q3. The ratio has improved, as 272 investment professionals opened new and increased positions, while 259 reduced and sold their positions in Cerner Corp. The investment professionals in our database now own: 251.96 million shares, down from 263.89 million shares in 2017Q3. Also, the number of investment professionals holding Cerner Corp in top ten positions decreased from 7 to 5 for a decrease of 2. Sold All: 42 Reduced: 217 Increased: 194 New Position: 78.

AcelRx Pharmaceuticals, Inc. (ACRX) formed multiple bottom with $2.33 target or 3.00% below today’s $2.40 share price. AcelRx Pharmaceuticals, Inc. (ACRX) has $122.49 million valuation. The stock decreased 2.04% or $0.05 during the last trading session, reaching $2.4. About 472,568 shares traded or 1.83% up from the average. AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) has declined 27.87% since May 1, 2017 and is downtrending. It has underperformed by 39.42% the S&P500.

The stock decreased 1.99% or $1.18 during the last trading session, reaching $58.25. About 2.68M shares traded. Cerner Corporation (CERN) has declined 2.77% since May 1, 2017 and is downtrending. It has underperformed by 14.32% the S&P500.

Since January 1, 0001, it had 0 insider purchases, and 4 sales for $37.88 million activity.

Cerner Corporation designs, develops, markets, installs, hosts, and supports health care information technology, health care devices, hardware, and content solutions for health care organizations and clients in the United States and internationally. The company has market cap of $19.32 billion. The firm offers Cerner Millennium architecture, which includes clinical, financial, and management information systems that allow providers to access an individualÂ’s electronic health record at the point of care, and organizes and delivers information for physicians, nurses, laboratory technicians, pharmacists, front- and back-office professionals, and consumers. It has a 22.67 P/E ratio. It also provides HealtheIntent platform, a cloud platform that enables organizations to aggregate, transform, and reconcile data across the continuum of care, as well as assists to enhance outcomes and lower costs.

Ratings analysis reveals 13% of Cerner’s analysts are positive. Out of 8 Wall Street analysts rating Cerner, 1 give it “Buy”, 1 “Sell” rating, while 6 recommend “Hold”. The lowest target is $52.0 while the high is $67.0. The stock’s average target of $58.75 is 0.86% above today’s ($58.25) share price. CERN was included in 8 notes of analysts from September 19, 2016. The firm has “Underweight” rating by Morgan Stanley given on Tuesday, December 13. On Wednesday, November 2 the stock rating was maintained by Deutsche Bank with “Buy”. The stock of Cerner Corporation (NASDAQ:CERN) has “Neutral” rating given on Monday, September 19 by Bank of America. The company was downgraded on Wednesday, November 2 by Robert W. Baird. Barclays Capital downgraded the stock to “Equal Weight” rating in Thursday, January 19 report. Citigroup downgraded Cerner Corporation (NASDAQ:CERN) on Friday, February 24 to “Neutral” rating. Oppenheimer downgraded the stock to “Perform” rating in Friday, February 10 report. The firm has “Mkt Perform” rating given on Thursday, December 1 by Leerink Swann.

Generation Investment Management Llp holds 7.12% of its portfolio in Cerner Corporation for 10.90 million shares. Prentiss Smith & Co Inc owns 130,071 shares or 4.27% of their US portfolio. Moreover, Cim Llc has 3.74% invested in the company for 141,477 shares. The New York-based Sandhill Capital Partners Llc has invested 2.91% in the stock. Senzar Asset Management Llc, a New York-based fund reported 169,000 shares.

Investors sentiment increased to 0.83 in 2017 Q4. Its up 0.13, from 0.7 in 2017Q3. It is positive, as 8 investors sold AcelRx Pharmaceuticals, Inc. shares while 15 reduced holdings. 7 funds opened positions while 12 raised stakes. 4.57 million shares or 31.27% less from 6.65 million shares in 2017Q3 were reported. Geode Cap Mgmt Ltd Liability Company reported 215,834 shares or 0% of all its holdings. Vanguard Group Inc Inc holds 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 1.55 million shares. Barclays Plc accumulated 904 shares. Moreover, Atlantic Tru Gru Limited Company has 0% invested in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 50 shares. Meeder Asset Mngmt Inc holds 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 1,300 shares. Natixis reported 107,000 shares stake. Cambridge Inv Research holds 0% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 14,688 shares. Virtu Fincl Limited Company reported 0.01% stake. Art Advisors Limited Liability holds 0.01% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) for 137,398 shares. Royal Fincl Bank Of Canada holds 30,390 shares or 0% of its portfolio. Wells Fargo & Mn reported 0% stake. Joel Isaacson And Limited Liability stated it has 0.02% of its portfolio in AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX). Credit Suisse Ag accumulated 14,009 shares or 0% of the stock. Cornerstone Cap Inc holds 0.01% or 40,000 shares. D E Shaw And reported 64,783 shares stake.

Cerner Corporation (NASDAQ:CERN) Institutional Positions Chart